TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8243427

Group type: EXPERIMENTAL
Intervention: AHA type diet
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 37
Study: 2418292

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg, intravenously)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29764639

Group type: EXPERIMENTAL
Intervention: Web-based SP encounter via video conference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face SP encounter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based SP encounter
Number of subjects: 0
Study: 28757108

Group type: EXPERIMENTAL
Intervention: Nifedipine + Celastrol
Number of subjects: 626

Group type: COMPARATOR
Intervention: Nifedipine + Placebo
Number of subjects: 626
Study: 25127927

Group type: EXPERIMENTAL
Intervention: Alcohol session (.82 g/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 17
Study: 23458986

Group type: EXPERIMENTAL
Intervention: Sugared PEG solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard PEG solution
Number of subjects: 100
Study: 22003206

Group type: EXPERIMENTAL
Intervention: Oncologists' assessment of supportive care needs and symptoms
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Oncologists' assessment of physical symptoms
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Oncologists' assessment of borderline/clinical depression and anxiety
Number of subjects: 408
Study: 18606533

Group type: EXPERIMENTAL
Intervention: SFC250
Number of subjects: 476

Group type: COMPARATOR
Intervention: SFC100
Number of subjects: 476

Group type: COMPARATOR
Intervention: FP250
Number of subjects: 476
Study: 16464715

Group type: EXPERIMENTAL
Intervention: Cardiac MIBG imaging (H/M [d] <1.7)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cardiac MIBG imaging (CAN diagnosed by H/M [d] and coefficient variance of RR interval)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Follow-up period of 7.2+/−3.2 years
Number of subjects: 144
Study: 14564460

Group type: EXPERIMENTAL
Intervention: Synthetic lycopene (Lycovit 10%, 15 mg/day for 28 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tomato-based lycopene (Lyc-O-Mato, 15 mg/day for 28 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (without lycopene, 15 mg/day for 28 days)
Number of subjects: 36
Study: 10670117

Group type: EXPERIMENTAL
Intervention: 3 mg/kg tramadol (Group T)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3 micrograms/kg fentanyl (Group F)
Number of subjects: 40
Study: 8965951

Group type: EXPERIMENTAL
Intervention: Infusion of lymphocytes from the original bone marrow donor
Number of subjects: 28
Study: 1365472

Group type: EXPERIMENTAL
Intervention: naproxen (500 mg b.d.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: diclofenac (50 mg t.i.d.)
Number of subjects: 100
Study: 6883914

Group type: EXPERIMENTAL
Intervention: Chloroquine 2 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chloroquine 3 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chloroquine 5 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chloroquine 10 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chloroquine 15 mg/kg
Number of subjects: 45
Study: 30239412

Group type: EXPERIMENTAL
Intervention: Bougie facilitated intubation
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Supraglottic airways (SGA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 3
Study: 26817643

Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation of tracts (PIT) with 21 Gy in three fractions
Number of subjects: 374

Group type: COMPARATOR
Intervention: No prophylactic irradiation of tracts (Control)
Number of subjects: 374
Study: 24290286

Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg twice daily for 3 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 22180344

Group type: EXPERIMENTAL
Intervention: MAID/RT regimen (mesna, Adriamycin, ifosfamide, dacarbazine) with 3 cycles of preoperative chemotherapy and 44 Gy of RT followed by surgery and 3 cycles of postoperative MAID, with additional 16 Gy of RT for positive surgical margins.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (historical matched-control patients).
Number of subjects: 48
Study: 20431612

Group type: EXPERIMENTAL
Intervention: Subthreshold diode laser photocoagulation (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Threshold diode laser photocoagulation (group B)
Number of subjects: 20
Study: 17962233

Group type: EXPERIMENTAL
Intervention: Negotiating individual blood pressure goals with patients
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: General population characteristics (e.g., gender, BMI, smoking status)
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Age and duration of diabetes
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 1534
Study: 16199633

Group type: EXPERIMENTAL
Intervention: Vaginal descensus (anterior, posterior, and maximum)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Seeing or feeling a bulge
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Obstructive urinary symptoms
Number of subjects: 270

Group type: COMPARATOR
Intervention: Urinary incontinence or bowel symptoms
Number of subjects: 270
Study: 12016598

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10516349

Group type: EXPERIMENTAL
Intervention: L-carnitine (10 mg/kg intravenously at the end of each hemodialysis session for 4 months)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (intravenously at the end of each hemodialysis session for 4 months)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-carnitine (in vitro incubation)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (in vitro incubation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8607053

Group type: EXPERIMENTAL
Intervention: Modified peribulbar block
Number of subjects: 408

Group type: COMPARATOR
Intervention: Standard retrobulbar block combined with facial nerve block of the O'Brien type
Number of subjects: 408
Study: 1804788

Group type: EXPERIMENTAL
Intervention: Regimen I: daily single-dose treatment with 200 mg of ofloxacin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Regimen II: every two week multidose treatment with 3 x 200 mg/day of ofloxacin
Number of subjects: 51
Study: 7068895

Group type: EXPERIMENTAL
Intervention: Habit reversal treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Negative practice treatment
Number of subjects: 10
Study: 31090440

Group type: EXPERIMENTAL
Intervention: Bilateral posterior quadratus lumborum blockade with 25-30 mL of 0.25% levobupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral posterior quadratus lumborum blockade
Number of subjects: 60
Study: 29423410

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) administered intravenously during surgery
Number of subjects: 60
Study: 26372470

Group type: EXPERIMENTAL
Intervention: Medication monitor
Number of subjects: 4173

Group type: EXPERIMENTAL
Intervention: Combined (medication monitor + text messaging)
Number of subjects: 4173

Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 4173

Group type: COMPARATOR
Intervention: Control (no reminders)
Number of subjects: 4173
Study: 24217301

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g orally)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vitamins C + E (2 g vitamin C with 600 mg vitamin E orally)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 93
Study: 21923417

Group type: EXPERIMENTAL
Intervention: Simplified urethropexy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group without urethropexy
Number of subjects: 104
Study: 18821157

Group type: EXPERIMENTAL
Intervention: Telerehabilitation using the Apraxia Battery for Adults - 2 (ABA-2)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Face-to-face assessment using the Apraxia Battery for Adults - 2 (ABA-2)
Number of subjects: 11
Study: 17368451

Group type: EXPERIMENTAL
Intervention: Balloon catheter
Number of subjects: 229

Group type: COMPARATOR
Intervention: Cervical vacuum cup
Number of subjects: 229
Study: 15168289

Group type: EXPERIMENTAL
Intervention: V.A.C. therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional conservative therapy
Number of subjects: 11
Study: 10896709

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 5
Study: 8881671

Group type: EXPERIMENTAL
Intervention: Targeted advertising designed to attract high-risk individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-targeted advertising requesting individuals who felt at risk of skin cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted advertising
Number of subjects: 0
Study: 1592346

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (600 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) plus Ursodeoxycholic acid (600 mg/day)
Number of subjects: 8
Study: 3922503

Group type: EXPERIMENTAL
Intervention: Hypochlorhydria after transient illness
Number of subjects: 6
Study: 2439007

Group type: COMPARATOR
Intervention: 1 microgram intradermal HBV vaccine given to neonates with BCG, followed by two doses of 1.0 microgram intradermal HBV vaccine.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Two doses of 2 micrograms HBV vaccine intradermally after a 20 micrograms intramuscular dose or three doses of 2 micrograms intradermally.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 4 micrograms of HBV vaccine given intradermally to 20 young children with a multiple orifice head fired by a jet gun.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group received 20 micrograms HBV intramuscularly followed by two 10 micrograms doses intramuscularly.
Number of subjects: 32
Study: 31786135

Group type: EXPERIMENTAL
Intervention: CPCB‐RPE1 implant (3.5×6.25 mm)
Number of subjects: 16
Study: 29598986

Group type: EXPERIMENTAL
Intervention: RMT with aromatic oil (RA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: RMT without aromatic oil (RM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standardised sham massage (SM)
Number of subjects: 44
Study: 28162037

Group type: EXPERIMENTAL
Intervention: Couples-level, telephone-based behavioral intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Individual intervention
Number of subjects: 198
Study: 26595968

Group type: EXPERIMENTAL
Intervention: Multi-channel electrical stimulation and microcurrent therapy
Number of subjects: 0
Study: 23230124

Group type: COMPARATOR
Intervention: 0 mg zeranol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 12 mg zeranol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 24 mg zeranol
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 36 mg zeranol
Number of subjects: 144
Study: 21907949

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) with clopidogrel (300 mg loading dose before TAVI, followed by 75 mg daily for 3 months) plus aspirin (100 mg lifelong)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone (100 mg lifelong)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin
Number of subjects: 0
Study: 18560914

Group type: EXPERIMENTAL
Intervention: Serum neuron-specific enolase levels measured at 2, 24, and 48 hours after traumatic brain injury
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Serum neuron-specific enolase levels in patients who died within 30 days after trauma
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase as a biomarker
Number of subjects: 169
Study: 16816766

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Minimal Intervention Strategy (MIS)
Number of subjects: 305
Study: 12782826

Group type: EXPERIMENTAL
Intervention: Oral feeding (clear liquid diet on the first postoperative day, then advanced to a regular diet)
Number of subjects: 65

Group type: COMPARATOR
Intervention: TEP feeding (feeding through tracheoesophageal puncture, nothing orally until the seventh postoperative day)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oral feeding
Number of subjects: 65

Group type: COMPARATOR
Intervention: TEP feeding
Number of subjects: 65
Study: 10889118

Group type: EXPERIMENTAL
Intervention: Er:YAG laser vitrectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mechanical vitrectomy
Number of subjects: 30
Study: 8818186

Group type: EXPERIMENTAL
Intervention: L-lactic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D,L-lactic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-lactic acid
Number of subjects: 0
Study: 1429406

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg qd)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3900148

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 31843026

Group type: EXPERIMENTAL
Intervention: Educative article featuring a lay individual with personal experience of suicidality (n = 86)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Educative article featuring a mental health expert (n = 90)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Unrelated article (control group, n = 90)
Number of subjects: 266
Study: 30124584

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lorazepam (LZP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 29
Study: 27579836

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral cochlear implantation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unilateral cochlear implantation (noise side turned off)
Number of subjects: 19
Study: 25489410

Group type: EXPERIMENTAL
Intervention: Dark chocolate snacks plus sugar-free cocoa beverage (DC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-chocolate snacks plus sugar-free non-cocoa beverage (NC)
Number of subjects: 60
Study: 22145605

Group type: EXPERIMENTAL
Intervention: Endoloop ligature
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 45-mm stapler
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: One nonabsorbable Hem-o-lok clip
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 20508468

Group type: EXPERIMENTAL
Intervention: F+AnE
Number of subjects: 20

Group type: COMPARATOR
Intervention: G+AnE
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: F+AE
Number of subjects: 20

Group type: COMPARATOR
Intervention: G+AE
Number of subjects: 20
Study: 18569019

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) 5 microg/kg, o.d. for 5 days after adjuvant chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16055779

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 126
Study: 12434478

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic immunosuppression
Number of subjects: 0
Study: 10795673

Group type: EXPERIMENTAL
Intervention: Conservative therapy (n = 12)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Arthroscopic suture repair with access channels (n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Arthroscopic minimal central resection, intrameniscal fibrin clot and suture repair (n = 7)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (n = 11)
Number of subjects: 40
Study: 8636745

Group type: EXPERIMENTAL
Intervention: ICRF-187
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 1561036

Group type: EXPERIMENTAL
Intervention: Verbalization of sensations
Number of subjects: 120

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Disclosure of sensations
Number of subjects: 120

Group type: COMPARATOR
Intervention: Disclosure of thoughts
Number of subjects: 120
Study: 3885387

Group type: EXPERIMENTAL
Intervention: Noscapine (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codeine (60 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codeine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codeine (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30609212

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 29438808

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg qd)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27830980

Group type: EXPERIMENTAL
Intervention: MMC-augmented repair (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No MMC (Group A)
Number of subjects: 40
Study: 25897953

Group type: EXPERIMENTAL
Intervention: High-fat diet with 79% energy from fat
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-fat diet with 90% energy from fat
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mixed diet with 29% energy from fat
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Independent of diet
Number of subjects: 11
Study: 24401626

Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Cortical hormone
Number of subjects: 268
Study: 20516435

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (paclitaxel-carboplatin) followed by surgery
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (paclitaxel-carboplatin) after surgery
Number of subjects: 624

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 624
Study: 18086944

Group type: EXPERIMENTAL
Intervention: Lactotripeptides (200 mL dairy drink with 14 mg lactotripeptides)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Concentrated fermented milk lactotripeptides
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Enzymatic lactotripeptides
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Synthetic lactotripeptides
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 16150815

Group type: EXPERIMENTAL
Intervention: Smoke alarm give-away program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no smoke alarm give-away)
Number of subjects: 40
Study: 14522728

Group type: EXPERIMENTAL
Intervention: Beta-glucan-enriched barley (8.1-11.9 g beta-glucan/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (isoenergetic dose of 6.5-9.2 g glucose/d)
Number of subjects: 18
Study: 10330387

Group type: EXPERIMENTAL
Intervention: Atrial rate-adaptive pacing
Number of subjects: 97

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 97
Study: 7795837

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g of calcium carbonate)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (360 mg of magnesium diglycine)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 698
Study: 2046334

Group type: EXPERIMENTAL
Intervention: Heroin hydrochloride (3.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heroin hydrochloride (6.0 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Free morphine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Total morphine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Morphine and codeine administration
Number of subjects: 6
Study: 7446455

Group type: EXPERIMENTAL
Intervention: Vitamin C, 800 mg four times daily for 2 days before surgery and 2 weeks after surgery
Number of subjects: 175

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 175
Study: 30821047

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 25 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28235249

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Secukinumab (both doses)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 25886846

Group type: EXPERIMENTAL
Intervention: Bespoke recruitment procedures involving hospital therapists screening patients and making referrals to the trial team.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Inclusive recruitment and watchful waiting strategies.
Number of subjects: 94
Study: 23478477

Group type: EXPERIMENTAL
Intervention: 1-hour flotation REST session
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1-hour seated control (passive recovery)
Number of subjects: 24
Study: 21317198

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 558

Group type: COMPARATOR
Intervention: Intramuscular benzathine penicillin G (IM BPG)
Number of subjects: 558
Study: 19744615

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (ICSK) 250 kU
Number of subjects: 95

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 95
Study: 17878421

Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis (6 times weekly)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 times weekly)
Number of subjects: 52
Study: 15562842

Group type: EXPERIMENTAL
Intervention: CABG+TMLR
Number of subjects: 44

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 44